--- title: "NRX Pharmaceuticals (NRXP) news: offering and Nasdaq notice" url: "https://aibio.space/companies/nrx-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NRXP offering and Nasdaq notice news: NRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms. NRX Pharmaceuticals, Inc." --- NRXP NRX Pharmaceuticals, Inc. NASDAQ · United States # NRX Pharmaceuticals (NRXP) news NRXP offering and Nasdaq notice news Listings · 2026-01-16 ## [NRX Pharmaceuticals gets Nasdaq notice for missing annual meeting deadline](https://aibio.space/news/nrx-pharmaceuticals-gets-nasdaq-notice-missing-annual-meeting-deadline/) Nasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026. ## Latest NRX Pharmaceuticals news 1. 2025-09-12 Mergers [NRx Pharmaceuticals completes acquisition of Dura Medical clinics through HOPE unit](https://aibio.space/news/nrx-pharmaceuticals-completes-acquisition-dura-medical-clinics-through/) NRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares. 2. 2025-09-08 Financings [NRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms](https://aibio.space/news/nrx-pharmaceuticals-says-8-8-million-raise-had-no-warrants-repricing/) The $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names. 3. 2025-08-14 Distress [NRx Pharmaceuticals files NT 10-Q, says second-quarter Form 10-Q will be late](https://aibio.space/news/nrx-pharmaceuticals-files-nt-10-q-says-second-quarter-form-10-q-will/) NRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date. 4. 2025-08-14 Distress [NRx Pharmaceuticals files late notice for quarterly report for June 30, 2025](https://aibio.space/news/nrx-pharmaceuticals-files-late-notice-quarterly-report-june-30-2025/) NRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures. ## NRX Pharmaceuticals at a glance - **Ticker**: NRXP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $26.7 million ### Related companies - [ANTHERA PHARMACEUTICALS INC](https://aibio.space/companies/anthera-pharmaceuticals/) OTC: ANTH - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Exelixis](https://aibio.space/companies/exelixis/) NASDAQ: EXEL - [Perrigo Company](https://aibio.space/companies/perrigo/) NYSE: PRGO - [NOVACCESS GLOBAL INC.](https://aibio.space/companies/novaccess-global/) OTC: XSNX - [NextCure](https://aibio.space/companies/nextcure/) NASDAQ: NXTC - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Pulmatrix](https://aibio.space/companies/pulmatrix/) NASDAQ: PULM ### Also on NASDAQ - [NEOGENOMICS INC](https://aibio.space/companies/neogenomics/) NEO - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) SGMT - [Seer](https://aibio.space/companies/seer/) SEER - [Pacira BioSciences](https://aibio.space/companies/pacira-biosciences/) PCRX - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX ## What NRX Pharmaceuticals does NRx Pharmaceuticals is a clinical-stage bio-pharmaceutical company developing treatments for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder and schizophrenia. Its drug candidates enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor. The three lead candidates are NRX-100, a preservative-free intravenous ketamine formulation, KETAFREE, a generic preservative-free ketamine formulation, and NRX-101, an oral fixed dose combination of D-cycloserine and lurasidone. The company is the founder and majority owner of HOPE Therapeutics, which offers interventional psychiatry care for treatment-resistant depression and PTSD using ketamine, transcranial magnetic stimulation, digital therapeutics and hyperbaric therapy. The company filed an Abbreviated New Drug Application for KETAFREE with priority review requested, and it expects to file a New Drug Application for NRX-100 in Q2 2026. | Product or program | What it is | Stage | |---|---|---| | NRX-100 | Preservative-free intravenous ketamine formulation for suicidal depression | NDA expected to be filed in Q2 2026; Fast Track Designation awarded | | KETAFREE | Generic preservative-free ketamine formulation for intravenous use | ANDA filed; commercial sales planned with FDA approval in Q3 2026 | | NRX-101 | Oral fixed dose combination of D-cycloserine and lurasidone | NDA initiated; Breakthrough Therapy Designation previously awarded | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/nrxp20251231_10k.htm). ## NRX Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | [$0](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | | Research and development | [$3.8 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | | Net income (loss) | [-$28.6 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | [-$25.1 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | | Cash from operations | [-$14.1 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | | Cash and equivalents | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926028027/) | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NRX Pharmaceuticals Has NRX Pharmaceuticals raised money recently? Our latest story on this, dated Sep 8, 2025: "NRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nrx-pharmaceuticals-says-8-8-million-raise-had-no-warrants-repricing/). Has NRX Pharmaceuticals received a Nasdaq deficiency notice? Our latest story on this, dated Jan 16, 2026: "NRX Pharmaceuticals gets Nasdaq notice for missing annual meeting deadline". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nrx-pharmaceuticals-gets-nasdaq-notice-missing-annual-meeting-deadline/). What is the ticker symbol of NRX Pharmaceuticals? NRX Pharmaceuticals, Inc. trades under the ticker NRXP on NASDAQ. Where is NRX Pharmaceuticals listed? NRX Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:B1Q; LSX:A4091K. What is the SEC CIK of NRX Pharmaceuticals? The SEC Central Index Key (CIK) for NRX Pharmaceuticals, Inc. is 1719406. Its filings are on SEC EDGAR. How many shares does NRX Pharmaceuticals have outstanding? 43,295,767 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is NRX Pharmaceuticals listed under? Our directory records NRX Pharmaceuticals, Inc. under United States. What does NRX Pharmaceuticals do? Our directory classifies NRX Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NRX Pharmaceuticals? The ISIN recorded for NRX Pharmaceuticals, Inc. is US6294442099. Does aibio.space cover NRX Pharmaceuticals? aibio.space lists NRX Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NRX Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does NRX Pharmaceuticals develop? NRx Pharmaceuticals is a clinical-stage bio-pharmaceutical company developing treatments for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder and schizophrenia. Its drug candidates enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor. What is NRX-100 from NRX Pharmaceuticals? NRX-100: Preservative-free intravenous ketamine formulation for suicidal depression Stage: NDA expected to be filed in Q2 2026; Fast Track Designation awarded. What is KETAFREE from NRX Pharmaceuticals? KETAFREE: Generic preservative-free ketamine formulation for intravenous use Stage: ANDA filed; commercial sales planned with FDA approval in Q3 2026. What was NRX Pharmaceuticals's revenue last year? $1.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: NRX Pharmaceuticals Members talk about NRX Pharmaceuticals (NRXP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NRX Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-06-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774926019194/nrxp20260601_424b5.htm) 2. 2026-05-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774926017397/nrxp20260331_10q.htm) 3. 2026-02-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774926004244/nrxp20260114_424b5.htm) 4. 2026-01-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774926001455/nrxp20260115_8k.htm) 5. 2025-11-26 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/nrxp20251125_8k.htm) 6. 2025-09-12 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925028949/nrxp20250912_8k.htm) 7. 2025-09-08 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925028567/nrxp20250908_8k.htm) 8. 2025-08-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925027184/nrxp20250817_424b5.htm) 9. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925026997/nrxp20250814_nt10q.htm) 10. 2025-01-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/nrxp20250128_8k.htm) 11. 2025-01-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/nrxp20250122_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NRXP on TradingView](https://www.tradingview.com/symbols/NASDAQ-NRXP/). ## SEC filings and registration - **SEC name**: NRX Pharmaceuticals, Inc. - **CIK**: 1719406 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NRXP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1201 ORANGE STREET, WILMINGTON, DE, 19801 - **Phone**: 484-254-6134 - **Shares outstanding**: 43,295,767 as of 2026-08-14 (10-Q filed 2026-08-14) - **Former names**: Big Rock Partners Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926032828/nrxp20261014_8k.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926032042/nrxp20261005_8k.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp20260915_8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030228/nrxp20260911_8k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/nrxp20260817_8k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1719406/000143774926028027/nrxp20260630_10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926026428/nrxp20260806_8k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm) filed 2026-07-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001719406), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NRX Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NRXP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NRX Pharmaceuticals, Inc. - **Ticker**: NRXP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6294442099 - **Other listed symbols**: GETTEX:B1Q; LSX:A4091K - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NRXP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nrx-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NRX Pharmaceuticals (NRXP) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/nrx-pharmaceuticals/